PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) Operating cash flow 2016–2025
PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$3.3MFY2025 · since FY2016: -$21.9M → -$3.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.3M | -1.3% |
| FY2024 | -$3.3M | -27.7% |
| FY2023 | -$2.6M | +15.4% |
| FY2022 | -$3.0M | -200.2% |
| FY2021 | -$1.0M | +75.2% |
| FY2020 | -$4.1M | +34.0% |
| FY2019 | -$6.2M | -18.9% |
| FY2018 | -$5.2M | +49.7% |
| FY2017 | -$10.3M | +52.8% |
| FY2016 | -$21.9M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PVCT financial trends
PVCT RevenuePVCT Net incomePVCT Net marginPVCT Gross profitPVCT Gross marginPVCT Operating incomePVCT Operating marginPVCT Free cash flowPVCT Capital expendituresPVCT Return on equityPVCT Stock buybacksPVCT Dividends paidPVCT Total assetsPVCT Total liabilitiesPVCT Shareholders’ equityPVCT overview →